newsfilter
← Latest News
GlobeNewswire·

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies Phase II study of GEN-1 in ovarian cancer 85% enrolled with full enrollment expected in the third quarter of 2022 FDA Allows GEN-1 + Avastin Phase II study LAWRENCEVILLE, N